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erative diseases, and protein folding disorders. To better understand Hsp90's roles in cellular pathologies and
in normal cells, numerous studies have utilized proteomics assays and related high-throughput tools to char-
acterize its physical and functional protein partnerships. This review surveys these studies, and summarizes
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Hsp90 is a molecular chaperone that is required for the viability of
eukaryotic cells [1,2]. It is frequently described as the core component
of a multimeric chaperone machine that functions in the folding, mat-
uration, stabilization and activation of other proteins. Hsp90 function
requires the binding and hydrolysis of ATP, which drives it through a
reaction cycle that appears to involve approximately four distinct
conformations [3–5]. Hsp90 works in concert with a cohort of co-
chaperones that modulate its binding and hydrolysis of ATP and its
interaction with protein substrates (a.k.a. “clients”) [6–9]. Since
these topics are covered in depth in other submissions to this special
edition, we will forgo a detailed discussion of Hsp90's reaction cycle
and the regulatory roles of its co-chaperones.
Most of the 200 plus proteins that have been found to interact
with Hsp90 were discovered to do so serendipitously, with Hsp90
and the client co-purifying as a complex, or co-precipitating in anti-
body pull-down assays. The discovery that geldanamycin [10] and
other compounds are highly speciﬁc Hsp90 inhibitors further ad-
vanced the ﬁeld, and small molecule Hsp90 inhibitors have become
invaluable tools for dissecting the functional signiﬁcance of Hsp90's
interactions with other proteins [7,11–14].
Because a comprehensive list of Hsp90's client proteins and regu-
latory subunits is available at the web site maintained by Dr. DidierPicard (http://www.picard.ch/downloads/downloads.htm), we will
not attempt to duplicate information available therein. Rather, this
review will concentrate on just those studies that have utilized high
throughput (HTP1) approaches to deﬁne the Hsp90 interacting prote-
ome, in the absence of a priori targets. Much of this discussion will
center on proteomics techniques, reﬂecting their potential and prom-
inence in assessing proteomes and protein interactions. Our discus-
sion will also include ﬁndings from powerful yeast studies directed
toward understanding the breadth and depth of Hsp90's roles in sup-
porting the cellular proteome. Although mass spectrometry has been
used to identify posttranslational modiﬁcations on speciﬁc individual
proteins, this review will only encompass proteomics studies, deﬁned
here as studies directed toward whole sets of proteins. Below, we will
introduce the HTP techniques that have been used to study Hsp90,
touching upon the general strengths and weaknesses of each ap-
proach. We will then brieﬂy survey results from studies that have
used these techniques. Finally, we will attempt a synthesis of these
ﬁndings and a description of how these studies have changed our per-
ceptions of this fascinating protein. The reader's attention is also di-
rected toward the Hsp90 interaction mapping initiatives from the
laboratories of Houry [15–17], Frydman [18], and Picard [19].
2. Overview of techniques
2.1. Hsp90 interactions
Most HTP studies of Hsp90 function are directed at identifying
Hsp90-interacting genes or gene products. However, this very term
“Hsp90-interacting” merits consideration. An Hsp90 interaction can
be a functional interaction, wherein manipulation of Hsp90 function
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end of the spectrum, this functional impact might be direct, wherein
compromised Hsp90 function manifests as a change in the expression
of an Hsp90-interacting protein (e.g., compromised expression of that
protein on a Western blot) or in some direct measure of its function
(e.g., cellular phosphotyrosine content). On the other end of the spec-
trum, a functional impact might be further removed, manifesting as
alterations in cellular growth, cell survival, or the phenotype of the
organism or cell. In this manifestation, “Hsp90 interaction”would de-
scribe a genetic interaction between Hsp90 and the Hsp90-interact-
ing gene/gene product. Typically, a detailed biochemical dissection
is required to determine the extent to which functional interactions
between Hsp90 and other genes or gene products are direct, versus
indirect interactions that are mediated by intermediary Hsp90-de-
pendent gene products.
Alternatively, “Hsp90 interaction” might describe the direct phys-
ical association of Hsp90 with a polypeptide. Physical interactions
with Hsp90 should probably be regarded as weak evidence that
Hsp90 modulates the function of a gene product (or vice versa), be-
cause protein–protein interactions are notoriously promiscuous in
vitro. Exacerbating this limitation, Hsp90 displays a highly charged
surface capable of binding a wide range of proteins, and Hsp90 is no-
toriously “sticky,” in that it binds non-speciﬁcally to a wide range of
inert chromatographic pull-down media. These facets of Hsp90 bio-
chemistry place certain burdens on studies assaying binding to
Hsp90 in the absence of evidence for a functional interaction. None-
the-less, Hsp90 binding is an extremely important part of the larger
puzzle, because it addresses the question of intermediary functional
interactions raised above. Throughout this review, we will use the
term “Hsp90-interacting” to describe both physical and functional as-
sociations with Hsp90.
An additional complication in studying interactions with Hsp90 is
the challenge of determining whether a given interaction reﬂects
Hsp90's chaperoning of a client substrate, versus an Hsp90 interac-
tion with a protein (e.g., a co-chaperone) that regulates Hsp90 func-
tion. Traditional criteria for making this distinction appear below,
elsewhere in this issue, and in the literature [9,20].
2.2. High throughput genetic screens
The ﬁrst attempts to identify novel Hsp90-interacting partners
were carried out by Susan Linquist's group, who screened Saccharo-
myces cerevisiae for mutations that were synthetically lethal when
combined with Hsp90 mutants [21], or for genes that functioned as
multi-copy suppressors of Hsp90 deﬁciencies [22]. The ﬁrst approach
screens for gene products whose function is required for cell growth
or viability under conditions where Hsp90's function is compromised,
while the latter approach screens for gene products whose overex-
pression restores the growth of cells that are Hsp90-deﬁcient.
Extending these studies, Hsp90's functional interactions have
been exhaustively mapped using synthetic genetic arrays (SGA),
and chemical-genetic screens for gene deletions that create hyper-
sensitivity to Hsp90 inhibition in yeast [16,18]. These genetic screens
are based on the logic that if a gene becomes essential when the func-
tion of Hsp90 is compromised, Hsp90 may be required for the proper
folding of a protein whose function overlaps with that of the deleted
gene [16]. While these assays do not readily ﬁt a classiﬁcation as “pro-
teomics,” any discussion of proteomics assessments of Hsp90 func-
tion would be incomplete without them.
In the SGA approach, the Houry group utilized a haploid query
strain expressing a temperature-sensitive allele of Hsp90 [16]. This
strain was crossed against approximately 4000 haploid strains, each
bearing a single deletion of a non-essential gene. Double-mutant hap-
loid progeny strains were then assessed for a combinatorial synthetic
growth defect, thus reporting a functional interaction between Hsp90
and the deleted gene/gene product.In the chemical-genetic approach, both the lab of Houry and the
lab of Frydman each propagated libraries of approximately 4000 via-
ble bar-coded yeast deletion mutants in the presence of the Hsp90 in-
hibitors geldanamycin or macbecin II (respectively) [16,18]. After
passage, DNA from surviving strains was isolated and assayed by mi-
croarray detection of the PCR-ampliﬁed gene-embedded bar codes. In
this assay for deletion-induced sensitivity, a genetic interaction with
Hsp90 results in the loss of the Hsp90-interacting strains from the
population, with this loss being evident in loss of signal on the bar-
code microarray assay.
Several criteria are used to validate the “hit lists” of candidate
Hsp90-interacting genes identiﬁed in these HTP genetic screens. One
criterion is the re-identiﬁcation of previously characterized Hsp90 co-
chaperone partners and known client families or pathways, thus vali-
dating the assay's ability to identify Hsp90 interactions. A second cri-
teria is the identiﬁcation of multiple components of an individual
cellular pathway or process, validating the conclusion that Hsp90 func-
tions in that pathway. A third criteria is that results from discrete assays
(performed in separate labs or using orthogonal genetic techniques)
demonstrate signiﬁcant overlaps in their lists of Hsp90-interacting
genes, validating the individual overlapping genes as high-conﬁdence
subsetswithin the larger HTP data. As a fourth criterion, subsequent de-
tailed characterizations have conﬁrmed Hsp90's interactions with indi-
vidual novel genes identiﬁed in the screen. Other more subtle
bioinformatic criteria have also been presented [18].
Though similar HTP genetic techniques have not been used to assess
Hsp90 function in human cells, highly speciﬁc small-molecule inhibitors
of Hsp90 have proven to have similar potential. In this approach, cells
are treated with Hsp90 inhibitor and subsequently analyzed using pro-
teomics techniques, thereby identifying sets of proteins whose expres-
sion is governed by Hsp90 function. This approach is analogous to
functional assays in Hsp90-deﬁcient yeast, but assesses direct changes
in protein expression rather than genetic deﬁciencies that compromise
growth.
Several criteria are available to validate results from inhibitor-based
proteomics studies of Hsp90 function. Based onwell-established prece-
dents, we should expect that an N-terminal Hsp90 inhibitor should in-
crease the expression of Hsp70 and (to a more limited extent) Hsp90.
Since both Hsp90 and Hsp70 are abundant and readily detected, this
is an easily achievable validating benchmark. Similar expectations ex-
trapolate to any other gene products regulated by HSF1, if they are ap-
parent in the proteomics data set.
As another validator, N-terminal Hsp90 inhibitors deplete Hsp90 cli-
ent proteins from treated cells. This seminal ﬁnding [10] has been dupli-
cated for nearly every Hsp90 client protein studied in detail, and is a
dogmatic hallmark of Hsp90 dependency. However, this criterion is a dif-
ﬁcult benchmark for proteomics assays of Hsp90 function: while most
Hsp90 clients are expressed at levels that are easily assayed by Western
blotting, it is much more difﬁcult to detect them using mass spectrome-
try. None-the-less, we might reasonably anticipate that when known
Hsp90 clients are detected, they should be down-regulated by Hsp90 in-
hibitors that target Hsp90's N-terminus. In these cases, and those above,
it is important to assess the whole dataset for these behaviors, and to
avoid cherry picking data that support the study's validitywhile ignoring
those that question it.
2.3. High throughput interaction screens
The strategies above focus on Hsp90 function, but physical inter-
actions between proteins are often the ﬁrst evidence of a functional
interaction. Thus, substantial effort has been directed toward identi-
fying proteins that bind to Hsp90. These studies often utilize afﬁnity
puriﬁcation of Hsp90, subsequently using one or more mass spec-
trometry-based assays to identify co-purifying proteins. Hsp90 has
been afﬁnity puriﬁed using antibodies that directly bind Hsp90, and
by expressing afﬁnity-tagged Hsp90 gene constructs. This second
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and C-termini, and with regards the large amounts of endogenous
Hsp90 expressed in normal cells. Afﬁnity approaches have also uti-
lized immobilized recombinant Hsp90 or Hsp90 domain constructs,
to “ﬁsh” Hsp90-binding proteins from cell lysates, and biotinylated-
geldanamycin to capture of Hsp90 complexes.
The criteria for validating hit lists of proteins that co-purify with
Hsp90 are similar to those described above to assess functional interac-
tions. As an additional validating criterion, control adsorptions per-
formed with inert afﬁnity media are required to address the speciﬁcity
the co-adsorptions; “Hsp90-binding” proteins should be much less
abundant in control adsorptions. Unfortunately, the importance of
using control resins to quantify non-speciﬁc binding is often overlooked.
Large-scale yeast two-hybrid screens have also been carried out to
identify novel Hsp90-binding proteins [16,23,24]. While the yeast
two-hybrid assay utilizes a genetic approach rather than mass spec-
trometry, it is fundamentally a proteomics technique, in that it is used
to answer questions about the functions and interactions of sets of pro-
teins. Yeast two-hybrid assays are typically validated using empty bait
vectors and other controls speciﬁc to the technique, and by conﬁrming
interactions using one of the co-adsorbing assays described above.
It is reasonable to expect that a functional Hsp90 partner, either
client or regulatory subunit, should also show a physical interaction
with Hsp90. Paired physical and functional interactions are apparent
in the large body of traditional studies, and represent the gold stan-
dard for demonstrating an Hsp90 partnership. Thus, one might simi-
larly expect a given protein to appear in hit lists both from HTP
assessments of Hsp90 binding and in hit lists from assessments of
Hsp90 function. This expectation is not always readily met, however,
due to the quantitative limitations discussed above, and due to exper-
imental challenges (discussed below). When observed, however, HTP
evidence for both physical and functional interactions can propel an
Hsp90-associated gene product to center stage.
2.3.1. Fractionation methodologies for identifying interacting proteins
In addition to understanding the rationale behind HTP assays of
Hsp90 interactions, it is important to appreciate how the strengths
and weaknesses of the downstream proteomics analyzes inﬂuence
our perception of Hsp90 function. Two-dimensional polyacylamide gel
electrophoresis (2D-PAGE) has frequently been utilized to separate, de-
tect, and quantify cellular responses to Hsp90 inhibition, and to assay
the Hsp90 interactome [25,26]. 2-D PAGE is a technically challenging
technique [27], and it can be difﬁcult to achieve the reproducibility re-
quired to accurately align gels. However, researchers fromdiverse back-
grounds can readily assess 2-D PAGE images of the Hsp90-associated
proteome. Thus, published images of Hsp90-associated proteomes typ-
ically speak for themselves, and gel displays of Hsp90-interacting pro-
teomes published to date have generally been quite good.
However, only ﬁnite amounts of material can be loaded onto 2-D
PAGE gels [28], hence these assays only detect the most abundant pro-
teins in the Hsp90-dependent proteome or the Hsp90-binding interac-
tome. This limit predicts that gel-based assays of Hsp90 function or
Hsp90 inhibition are probably incapable of detecting Hsp90 clients.
Similarly, gel-loading limits probably make them incapable of detecting
rare Hsp90 subunits. It is also important to recall that some proteins
(e.g., membrane proteins) are not readily tractable to analysis by 2-D
PAGE [28–30]. These limitations argue that gel-based studies performed
to date are unlikely to have fully probed the Hsp90 interactome.
We should also appreciate that gel based assays may understate the
biological range of variances in assays of Hsp90's associations. This ca-
veat acknowledges the poor quantitative response of silver staining
[31], a technique frequently used to visualize the Hsp90-associated pro-
teome. Modern ﬂuorescent stains address these limits [31], but these
are recent arrivals relative the body of Hsp90 studies discussed below.
Difference gel electrophoresis, or DIGE [32], has also been used to assess
Hsp90 function, providing a large dynamic response range andaddressing many of the problems with gel-to-gel irreproducibility.
This addresses the dynamic range compression characteristic of silver-
stained images, and provides a particularly strong quantitative
assessment.
2.3.2. Mass spectrometry methods for identifying protein interactors
In addition to detecting and quantifying proteins on gels, it is also
necessary to identify them. In the past two decades, mass spectrome-
try (MS) techniques have almost wholly replaced other protein iden-
tiﬁcation methods such as Edman protein sequencing and Cleveland
mapping [33].
Several Hsp90 proteomics studies have utilized the MS technique of
peptidemass ﬁngerprinting to identify unknown proteins [15,16,25,34–
36]. This somewhat outdated approach is capable of identifying proteins
that are well-resolved from each other, e.g., 2-D PAGE spots [27,37–41].
However, this technique requires careful, skeptical evaluation of each
bioinformatic protein “identiﬁcation.” Fortunately, Hsp90 studies utiliz-
ing this technique show the hallmarks of conservative interpretation,
and the proteins thus identiﬁed are consistent with our understanding
of Hsp90.
Due to its weaknesses, peptide mass ﬁngerprinting has largely
been replaced by approaches that utilize tandem mass spectrometry
(MS/MS). Protein identiﬁcations by MS/MS are more conﬁdent than
those obtained by peptide mass ﬁngerprinting. MS/MS approaches
also eliminate the need that proteins be perfectly resolved from
each other [41].
The ability of MS/MS to directly assay protein mixtures has also
given advent to gel-free chromatographic proteomics approaches
[42,43]. These approaches are well capable of identifying hundreds
to thousands of Hsp90-associated proteins in a single protein sample.
Gel-free approaches have also been coupled to sophisticated strate-
gies in which separate Hsp90-associated proteomes (e.g., inhibitor-
treated vs. untreated) are covalently labeled with different isotopic
tags (e.g., ICAT [44] or iTRAQ [45]), then pooled prior for analysis by
LC–MS/MS. Like the DIGE approach above, this reduces the impacts
of technical variability.
It is also important to appreciate that the advent of gel-free chromato-
graphic proteomics strategies leaves us with two very different scenarios
with regards to a protein's identiﬁcation by MS/MS. Protein identiﬁca-
tions basedupon theMS/MS fragmentation of numerous unique peptides
from each protein are typically regarded with a high degree of conﬁ-
dence, regardless of whether the protein was isolated from a gel or not.
On the other hand, chromatographic approaches may also yield protein
identiﬁcations based upon only a few peptides from the parent protein,
potentially diminishing conﬁdence. Identiﬁcations based upon only a sin-
gle peptide (“one hit wonders”) have traditionally been regarded with
skepticism, though this prejudice may be unjustiﬁed [46].
Most proteomics experiments are discovery surveys, wherein mass
spectrometry is used to identify unknownproteins and to detect changes
in protein expression in the absence of a priori targets. In theseMS tech-
niques, themass spectrometer is programmed to scan thewhole peptide
population, and to use sophisticated real-time data-dependent strategies
to select predominant peptides for MS/MS fragmentation [47].
In contrast, mass spectrometers can also be programmed with fore-
knowledge of the proteins of interest [48]. Examples include selected
ion monitoring (SIM) [49,50], selected reaction monitoring (SRM) [48],
and multiple reaction monitoring techniques (MRM) [51]. In these as-
says, the mass spectrometer is “blinded,” being programmed to look
only for speciﬁc peptide ion targets and their fragments. This turns the
mass spectrometer into an exquisitely speciﬁc chromatography detec-
tor, yielding chromatographic peaks that can be used to quantify
Hsp90-associated proteins. Because this specialized technique cannot
discover changes in the proteome in the absences of a priori targets, it
is reserved for mature proteomics questions.
Proteomics assays of Hsp90 function also face bioinformatic chal-
lenges. Due to lack of uniformity in database indexing and protein
659S.D. Hartson, R.L. Matts / Biochimica et Biophysica Acta 1823 (2012) 656–667nomenclature, it can be challenging to compare proteins identiﬁed
from different databases or different model organisms. Even in a sin-
gle database, a given protein sequence is typically represented by
more than one name and accession number. An even more difﬁcult
challenge is created by true biological complexity within an individu-
al species' proteome. A “single” organism's genome (and hence its se-
quence databases) often includes multiple protein homologues, point
mutants, splice isoforms, pseudogenes, and sequencing errors, mak-
ing it challenging to correctly assign a single gene product to the “cor-
rect” representative sequence in the database [52,53].
An authentic biological mixture of related gene products creates
similar challenges [54]. Mass spectrometry data are not always capa-
ble of distinguishing between multiple protein isoforms. 2-D PAGE
can be useful in resolving such mixes, but can also be compromised
by degradation or covalent derivatization in vitro. To be fair, the
issue of protein isoforms is certainly not speciﬁc to mass spectrome-
try techniques: most antibodies and many gene probes face similar
challenges. None-the-less, it is helpful to remember that mass spec-
trometers do not actually sequence proteins, and that “identiﬁca-
tions” of Hsp90-interacting proteins are bioinformatic conclusions.
Thus, it is sometimes helpful to consider an “identiﬁed” protein as a
protein archetype or an operational deﬁnition.
As is the casewith a popular and rapidly evolving technique, diverse
early proteomics studies variedwidely in their quality. In response, Carr
et al. [55] proposed general standards for the publication of proteomics
research. In 2006, an international group reﬁned the Carr standards to
produce the “Paris” guidelines [56]. To keep abreast of technical devel-
opments and data archiving resources, the Paris guidelineswere further
revised in 2009, to produce the Philadelphia guidelines [57]. These stan-
dards or their journal-speciﬁc variants are now widely regarded as es-
sential practices in the ﬁeld of proteomics. Like other disciplines, the
body of published Hsp90 proteomics studies show numerous gaps rel-
ative to thesemodern standards,with the impacts of these gaps ranging
from trivial to consequential.
3. Studies assessing Hsp90's physical interactions with proteins
Below, we brieﬂy survey studies of the Hsp90-binding proteome.
These studies are summarized in Tables 1A and 1B. We have also
complied a master list that includes most of the proteins identiﬁed
in these studies (Supplementary Table 1A), with an emphasis on the
human Hsp90 interactome. Where appropriate, we have attempted
to identify human homologues of yeast Hsp90-binding proteins.
From a total of 289 Hsp90-binding proteins thus compiled, 56 have
been found in more than one study, of which 28 have been previously
described as known or putative Hsp90 associates. We also include the
interactomes of some of Hsp90's better-characterized co-chaperones
(Supplementary Table 1D). We also call the reader's attention to
Avrom Caplan's study in which a yeast strain expressing mutant
Cdc37 was used to identify 51 Cdc37-dependent protein kinases [58].
Te et al. [25] utilized the 8D3 monoclonal anti-Hsp90 antibody to
purify Hsp90 chaperone machinery from Dounce homogenates of
human Jurkat lymphona cells, displayed these co-adsorptions on 1-
D and 2-D PAGE gels and identiﬁed individual proteins by peptide
mass ﬁngerprinting. Irrelevant antibody was used to validate the
speciﬁcity of the adsorptions. They also used a truncated Hsp90 C-ter-
minus to ﬁsh Hsp90-binding proteins from cell lysates in vitro. They
identiﬁed 23 Hsp90-interacting proteins, including 6 novel interac-
tions. The high prevalence of known Hsp90 co-chaperones likely re-
ﬂects limitations in gel loading and the sensitivity of colloidal
Coomassie Blue staining utilized. They also observed human homo-
logs of Pih1, RVB1L, and RVB2L, suggesting that the Hsp90 complex
previously described in yeast [16] was conserved in human cells.
Their Hsp90 interactome also included RPAP3/hSpagh (FLJ21908),
which was subsequently shown to be a co-chaperone involved in
the Hsp90-dependent assembly of RNA polymerase II complexes[59], and to function in an snRNP assembly complex [60]. The pres-
ence of Hsp90-bound tubulin further suggested interactions between
Hsp90 and microtubule machineries.
Skarra and co-workers [61] utilized Flag afﬁnity-tagged Hsp90 to
isolate Hsp90-bound proteins in HEK293 cells. The negative control
consisted of Flag-tagged pull downs of extracts from cells expressing
the Flag-tag alone. Their Hsp90 interactome was analyzed by direct
solution trypsinolysis and LC–MS/MS analysis. As quantitative cri-
teria, they conducted statistical analysis of spectral count data, incor-
porating control puriﬁcation data to calculate a probability score for a
true interaction between two proteins [61]. Results identiﬁed 27
Hsp90-binding proteins, consisting primarily of Hsp90 co-chaperone
partners and various isoforms of tubulin. Unique gene products iden-
tiﬁed in the screen include: PDRG1, a p53 regulated gene; SSB1;
GIGYF2, mutants of which are associated with Parkinson's disease
(Park11); and IRS4.
Wang et al. [26] used immobilized 9D2 anti-Hsp90αmonoclonal an-
tibody to co-immunoadsorb Hsp90 complexes from HCT-116 colon
cancer cell lysates. Control resins consisted of mock-coupled agarose.
The Hsp90-binding proteome was displayed by 2-D PAGE, and 43
Hsp90-associated proteins were identiﬁed by mass spectrometry (al-
though supporting proteomic/bioinformatic parameters were not pro-
vided). In addition to the expected identiﬁcation of Hsp90 associated
co-chaperones, they identiﬁed protein components of the cytoskeleton,
proteins involved in RNA processing and proteins modulating protein
turnover via ubiquitination and proteasome degradation.
Falsone et al. [62] used the AC88 monoclonal antibody to isolate
Hsp90-binding proteins from HEK297 cells. Naïve protein-G agarose
resin was used as the negative control. They identiﬁed 40 candidate
Hsp90-binding proteins, 29 of which were novel, including metabolic
enzymes, cytoskeleton components and components of the cell's pro-
tein synthesis apparatus. Only three of Hsp90's co-chaperones were
co-adsorbed (Hsp70, Hsp105 and TCP-1), and only ﬁve of their novel
interactors were apparent in other studies. As the authors note, this
may reﬂect properties of the AC88 antibody, whose epitope is masked
in most previously described Hsp90 complexes.
Tsaytler and co-workers [63] used three complementary proteomic
approaches to identify novel Hsp90 interactors: co-immunoadsorption
with F-8 anti-Hsp90 monoclonal antibody, ﬁshing in lysates using
immobilized recombinant Hsp90β, and, afﬁnity capture of Hsp90 with
biotinylated-geldanamycin. Control resins consisted of irrelevant HA-
tag antibody bound to protein-G agarose, mock coupled resin, and
naïve NeutAvadin beads, respectively. Co-adsorbing proteins were sep-
arated on 10% SDS-PAGE gels, which were subsequently cut into 20
slices for in-gel trypsinolysis, and identiﬁedbynano-sprayMS/MS. Thir-
teen of the 44 identiﬁed proteins were identiﬁed by more than one ap-
proach, 18 of the 44 were novel associations, and 12 of the 44 were
known co-chaperones. Cytoskeletal components, and components of
the protein synthesis and RNA processingmachineries were also prom-
inent in the study.
Gano and Simon [64] utilized tandem afﬁnity puriﬁcation of N- and
C-terminal tagged Hsp90 fromHEK293T cell lysates, tagging both wild-
type Hsp90α and an Hsp90 mutant capable of binding, but not hydro-
lyzing ATP. Hsp90 was captured in the presence of an ATP, ADP, or gel-
danamycin. Lysates from cells transfected with empty vector were used
as negative controls. The Hsp90-bound proteomes were assayed using
the quantitative spectrum counting technique, thus identifying statisti-
cally signiﬁcant changes in the Hsp90 conformations to which the pro-
teins bound. They identiﬁed 37knownHsp90partners, 20 ofwhichwere
co-chaperones, as well as 28 novel associations. Seven of the proteins
contained tetratricopeptide repeat (TPR) domains, and seven contained
CHORD-Sgt (CS) domains, both ofwhich are established Hsp90-interact-
ing motifs. Eight Hsp70 family members were also identiﬁed. This study
demonstrated the speciﬁcity of protein interactions for particular ligand-
bound forms (conformations) of Hsp90, providing considerable elabora-
tion to our understanding of the Hsp90 reaction cycle. The interaction of
Table 1A
Identiﬁcation of proteins that interact directly with the Hsp90 machine. Summary of studies to identify Hsp90 interacting proteins.
Studies Method Separation Identiﬁcation Cell system
Falsone et al. [62] Co-IP, anti-Hsp90 antibody 1D SDS-PAGE Nano-HPLC–MS/MS HEK293
Gano and Simon
[64]
TAP-tagged Hsp90α Solution digest Nano-HPLC–MS/MS with spectral
counting
HEK293T
Zhao et al. [16] TAP-tagged Hsc82 bait
2-Hybrid screen Hsp82 bait
1D SDS-PAGE
Solution digest
Peptide mass ﬁngerprinting MALDI-TOF
Nano-HPLC–MS/MS
S. cerevisiae
Millson et al. [23] 2-Hybrid screen Hsp82-bait S. cerevisiae
Skarra et al. [61] Flag-Hsp90α pull down Solution digest Nano-HPLC–MS/MS with spectral
counting
HEK293
Te et al. [25] Co-IP, anti-Hsp90 antibody
Hsp90αCT-agarose capture
1D SDS-PAGE
2D PAGE gels
Peptide mass ﬁngerprinting MALDI-TOF Jurkat
Tsaytler et al. [63] Co-IP, anti-Hsp90 antibody
Hsp90β-agarose pull down
Biotin-geldanamycin capture
1D SDS-PAGE Nano-HPLC–MS/MS A431 human epidermoid
carcinoma cells
Wang et al. [26] Co-IP anti-Hsp90α antibody 2-D PAGE gels MS HCT-116
Gong et al. [15] TAP-tagged Hsp90 or other molecular
chaperones
1D SDS-PAGE
Solution digest
Peptide mass ﬁngerprinting MALDI-TOF
Nano-HPLC–MS/MS
S. cerevisiae
Studies utilizing afﬁnity puriﬁcation techniques to isolate Hsp90 complexes are listed above together with studies using two-hybrid screens to identify interacting proteins. The
table summarizes the methods used to capture the complexes (Co-IP, co-immunoprecipitation; TAP, tandem afﬁnity puriﬁcation), separate components of the complexes, and
identify those components. The organism or cell line used for each study is also listed.
Table 1B
Identiﬁcation of proteins that interact directly with the Hsp90 machine. Summary of
studies to identify proteins that interact with Hsp90 cochaperones.
Studies Method and
cochaperone target
Separation Identiﬁcation Cell
system
Millson et al.
[24]
2-Hybrid screen:
Cdc37, CNS1, Sba1/p23
S. cerevisiae
Park et al.
[72]
TAP-tagged
Cyclophilin 40
1D SDS-
PAGE
Nano-HPLC–
MS/MS
HeLa
Echeverria
et al. [65]
Co-IP, anti-p23
antibody
1D SDS-
PAGE
Nano-HPLC–
MS/MS
T. gondii
Skarra et al.
[61]
Flag-PP5 pull down Solution
digest
Nano-HPLC–
MS/MS with
spectral
counting
HEK293
Song et al.
[73]
Co-IP, anti-Sti1/HOP
antibody
1D SDS-
PAGE
Nano-HPLC–
MS/MS
C. elegans
Studies utilizing afﬁnity puriﬁcation techniques to isolate co-chaperone complexes are listed
above together with studies using two-hybrid screens to identify interacting proteins. The table
summarizes the methods used to capture the complexes (Co-IP, co-immunoprecipitation; TAP,
tandem afﬁnity puriﬁcation), separate components of the complexes, and identify those
components. The organism or cell line used for each study is also listed.
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with 43 being signiﬁcantly over-represented in one ligand group versus
the others [64]. Their proteomics assays demonstrated that the previous-
ly described Hsp70/BAG2/DNAJC7/ST13(HIP) machineries preferentially
associated with geldanamycin-bound Hsp90. They also observed that
Hsp90 co-chaperones CDC37L1, RPAP3 and PIH1D1 interacted preferen-
tially with geldanamycin-bound Hsp90. In contrast, the co-chaperones
AHA1, p23, NUDC, CACYBP and UNC45A associated preferentially with
ATP-bound mutant HSP90, while CHORD1 interacted with ADP-bound
Hsp90. Of additional interest is the observation that a number of
known andputativeHsp90 clients either preferred to bind to geldanamy-
cin-boundHsp90 (MFL2, YTHDC2 andNR3C1/glucocorticoid receptor) or
the ATP-bound conformation of the mutant Hsp90 (CHUK/IKKalpha,
IKBKG, DYNC1H1, CALD1, MAP3K7IP1/2, LLRIQ2, SCRIB and CNOT6).
The authors note that seven of the 15 proteins, whose interactions with
Hsp90 were speciﬁcally enhanced by geldanamycin, are involved in
RNA metabolism, linking Hsp90 function to RNA synthesis and proces-
sing [64].
Millson and co-workers [23] conducted a two hybrid screen utiliz-
ing as bait an Hsp82(E33A) mutant that binds but does not hydrolyze
ATP, in an effort to stabilize Hsp90's interactions with clients. They
identiﬁed 177 gene products that interact with Hsp90, 46 of which
have putative human homologues (see Supplementary Table 1A).
The Hsp90 interactome thus identiﬁed includes co-chaperone part-
ners, metabolic enzymes, proteins involved in vesicular/protein
transport, protein synthesis, and signal transducers.
Zhao and co-workers [16] similarly conducted a two-hybrid
screen using Hsp90 as bait and a library of yeast genes as prey. In ad-
dition, they used TAP-tag pull downs from yeast, in conjunction with
solution digests and LC–MS/MS analysis of the Hsp90-binding prote-
ome. This study also included synthetic lethal and chemical-synthetic
lethal screens (discussed below). They identiﬁed a total 90 Hsp90-
binding proteins via the two-hybrid screen and 118 via TAP-tag pull
down, but only 10 of these interactions were common to both sets
of proteins. These overlapping proteins included Hsp82, Hsc82 and
5 co-chaperones. The proteins identiﬁed via the two-hybrid screen
in this study had minimal overlap with those identiﬁed by Millson
et al. [23] (4 genes with human homologues), perhaps reﬂecting the
different reporter constructs utilized to carry out the screens. Other
novel Hsp90 associations identiﬁed in this study suggest roles for
Hsp90 going far beyond chaperoning signal transduction, implicating
Hsp90 in ribosome biogenesis, regulation of chromatin structure, RNA
processing and vesicular/protein transport.
In an ambitious follow up study, Gong et al. [15] mapped protein
interactions with yeast molecular chaperones using a variety ofTAP-tagged chaperones as bait. The study identiﬁed 1154 Hsp90-
binding proteins: 433 binding to Hsc82 and 878 binding to Hsp82.
However, only 157 proteins are common to both sets, indicating
that discrete Hsp90 isoforms have distinct functions. Due to the
large number of candidate protein interactions discovered in these
surveys, we have not included their human counterparts in the list
compiled in Supplementary Table 1. However, we have included
these yeast gene lists in Supplementary Table 2A and B, adding our
own bioinformatic analyses and links. As originally noted by Gong
et al. [15] and McClellan et al. [18], results indicate that Hsp90 is in-
volved nearly every major physiological process in yeast, including
chromatin remodeling and DNA repair, RNA processing, and vesicle-
mediated transport. Gong et al. [15] suggest that Hsp90 function
may be delivered to these cellular processes by three known Hsp90
chaperone modules, and by 11 novel Hsp90-containing chaperone
modules.
For completeness here we include references to studies carried
out in Plasmodium falciparum and Toxoplasma gondii [65–67]. Howev-
er, the ﬁndings of these studies will not be discussed here as they are
the subject of another submission to this issue. We also include here a
reference to a proteomic study carried out to identify in vivo Hsp90-
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ents of bacterial HtpG have yet to be identiﬁed.
4. Studies assessing Hsp90's functional interactions with proteins
As mentioned in the Introduction, highly speciﬁc small-molecule
inhibitors of Hsp90 can be used to assess the Hsp90 dependent prote-
ome in mammalian cells. Below, we brieﬂy survey studies utilizing
this approach (Table 2). A list of gene products that were found to
functionally interact with Hsp90 in these studies is given in Supple-
mentary Table 1B.
Maloney et al. [34] used a gel-based proteomics approach to dem-
onstrate that 3% of the detectable A2780 ovarian cancer cell proteome
was sensitive to 17-AAG. Cellular responses to Hsp90 inhibition in-
cluded the up-regulation of the chaperone cassette regulated by
HSF1. Among the novel responses observed (see Supplementary
Table 1B), the authors went on to demonstrate that the down-regula-
tion of histone acetyltransferase and arginine methyl transferase ob-
served in the proteomics data were also apparent on Western blots,
and were accompanied by deﬁciencies in cellular acetylation. A phys-
ical interaction between PRMT5 with Hsp90 was demonstrated, and
subsequently, PRMT5 was conﬁrmed to be slowly depleted from
BT20 breast cancer cells treated with novel Hsp90 inhibitors [34].
Yao et al. [36] used silver-stained 2-D PAGE gels to assess ARPE-19 ret-
inal pigment epithelial cell cultures treated for 16 h with 3 μM 17-AAG.
Spots showing apparent changes in expression of more than 1.5-fold
were identiﬁed by peptide mass ﬁngerprinting. Although Hsp90 and
Hsp70 were not identiﬁable in the study, 94 other proteins showed al-
tered expression, and 87 of thesewere identiﬁable. Although signal trans-
ducers were not readily apparent, the inhibitor-sensitive sub-proteome
included components of pathways for glycolysis/gluconeogenesis, ubiqui-
tinylation/proteosome degradation, oxidative stress, and cytoskeleton
function.
Muroi et al. [35] used a gel-based approach to identify 20 HeLa
proteins whose expression was altered by geldanamycin. This study
is noteworthy due to its statistical assessment of changes in protein
expression, analyzed by DIGE assays of biological replicates. However,
the most important aspect of this study is its demonstration that pro-
teomics ﬁngerprints could be used to organize 21 different com-
pounds into clusters based upon their impacts on the proteome. In
this hierarchical cluster, radicicol and geldanamycin segregated into
a distinct branch from the other compounds. Furthermore, the MG-Table 2
High throughput assays of functional interactions with Hsp90.
Study Separation Quantitati
Malony et al. [34] 2-D PAGE Silver
Muroi et al. [35] 2-D PAGE DIGE
Falsone et al. [69] 2-D PAGE Coomassie
R-250
Shumacher et al. [70] Orthogonal
chromatography
ICAT
Song et al. [71] Orthogonal
chromatography
iTRAQ
Yao et al. [36] 2D-PAGE Silver
Remily-Wood et al. [51] SDS-PAGE Multiple
reaction
monitorin
McClellan et al. [18] Not applicable Not
applicable
Zhao et al. [16] Not applicable Not
applicable
Studies using screens to identify gene products that interact functionally with Hsp90 are lis
identiﬁed, together with the cell line used for the study are summarized. For deﬁnition of a132 inhibitor of the proteasome segregated into a different branch
of the same hierarchical tree as Hsp90 inhibitors, reﬂecting both sim-
ilarities and differences in their effects on cells. This successful and ac-
curate classiﬁcation of compounds into mechanistic families is an
important proof of the principle that drug mechanisms can be eluci-
dated on the basis of their impacts on the cellular proteome.
Falsone et al. [69] utilized another novel gel-based approach to
study Hsp90 function in HeLa cells. They analyzed the impacts of
dual treatments with proteasome inhibitors and radicicol, identifying
48 ubiquitinylated proteins that were recruited to the aggresome in
response to radicicol and MG-132. Among these proteins, 12 had
been previously implicated in physical or function interactions with
Hsp90, making the other 36 proteins high-probability candidates as
physical or functional partners of Hsp90.
Schumacher et al. [70] used a gel-free isotope-coding approach
(ICAT) to investigate the impact of geldanamycin in anaplastic large
cell lymphoma (ALCL) cells. Based upon a single-pass analysis, the au-
thors concluded that 68% of the quantiﬁable ALCL proteome was im-
pacted by Hsp90 inhibition. At ﬁrst glance, this impact seems
inconsistent with current models for Hsp90 as a highly speciﬁc chap-
erone, and with results obtained in other studies. Similarly, there are
several examples within their data set that conﬂict with previous re-
ports of the effects of Hsp90 inhibitors. This may reﬂect protein mis-
identiﬁcations, since their false-discovery rate (7%) was fairly high by
modern standards. However, it is also important to note that the af-
ﬁnity-selective ICAT approach appeared to sample a subset of the pro-
teome, because several abundant proteins were not apparent in the
dataset. Hence the relatively large drug impacts that they observed
may have reﬂected a non-uniform sampling of the proteome by the
afﬁnity tag ICAT reagent. Moreover, the authors usedWestern blotting
to conﬁrm the drug-induced up-regulation of four of their proteins
(USP9, GAP1, PCLN1, and STCN) and the down-regulation of four others
(TNKS, SOCS4, NEMO,OPG). Their ICAT data also suggested the depletion
of four kinases, and the somewhat surprising induction of three others.
Moreover, certain themes in this protein data set are echoed in other
proteomics studies. Also notable is that this study is one of the few pro-
teomics assays to address very early cellular responses to Hsp90 inhibi-
tion, utilizing 12 h drug treatments rather than the overnight drug
treatments that are more typically employed.
Song et al. [71] used a gel-free isotope coding approach (iTRAQ) to
characterize the effects of IPI-504 in a mouse xenograft model of tumor
cell biology. In two different explant tumors, assays demonstrated thaton Protein identiﬁcation System
MS 17-AAG
in A2780 cultures
MS GA and radicicol
in HeLa cultures
MS/MS MG132 vs. aggresome
in HeLa cultures
MS/MS GA
in ALCL cultures
MS/MS IPI-504 in vivo
MS 17-AAG
in ARPE-19 cells
g
LC-MRM 17-DMAG
in cancer cell lines
Chemical genetic
screen
S. cerevisiae
Synthetic lethal
and chemical
genetic screens
S. cerevisiae
ted above. The methods by which those components were separated, quantitated, and
cronyms see “Abbreviations”.
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while 4% was upregulated. Two of the proteins depleted (GOLPH2 and
MHC class IB protein) and two of those induced (bigycan and galectin-
3) were validated by immunohistochemical staining and by manual in-
spection of reporter ions in the primary MS/MS spectra. The most dra-
matic insight from this study was indications that tumor explants may
respond to Hsp90 inhibition quite differently than the same cells cul-
tured in vitro. Eleven protein kinases were quantiﬁed in their MS data,
but showed no consistent response to the in vivo drug regimen. The
only HSF1 cassette protein induced in vivowas Hsp70. Western blotting
conﬁrmed that several protein kinases (Her-2, p70S6K, AKT, MAPK)
were not depleted in explants treated in vivo, but the same tumor cells
cultured in vitro showed classic inhibitor-induced down regulation of
these Hsp90 client proteins. Thus, both the proteomics assays and the
traditional assays suggest cellular responses in vivo that challenge
models derived from Hsp90 inhibition in cultured cells.
Zhao et al. [16] employed SGA and chemical-genetic screens of
Hsp90 function to identify 451 candidate interactions with Hsp90,
49 of which were common to both functional assays. These overlap-
ping 49 genes represent an especially high-conﬁdence data subset.
Surprisingly, however, no Hsp90-interacting proteins were identiﬁed
as common to all four screens from the Houry group (two functional
screens and two physical screens). None-the-less, when their aggre-
gate set of functional interactions was compared to the aggregate
set of physical interactions, 22 genes/gene products were capable of
both binding to Hsp90 and compromising yeast growth.
McClellan et al. [18] also conducted a chemical-genetic screen for
Hsp90-interacting proteins, winnowing their large data sets by focus-
ing on the 5% of their mutant strains that showed the greatest growth
defects. Additionally, they conducted their screens at both 30 °C and
37 °C, observing dramatic temperature-dependent differences in
Hsp90's functional associations. Higher temperatures enrich Hsp90's
interactions with stress proteins, signal transducers and cell cycle
regulators, some metabolic proteins, and Hsp90's associations with
protein components of the MTOC, cytokinesis, and bud assemblies.
A comparison of the GS screens from the labs of Frydman [18] and
Houry [16] shows that 78 of 316 total chemical-genetic hits were
common to both labs. Other insights gained from these yeast screens
are discussed more fully below.
Remily-Wood et al. [51] used multiple reaction monitoring
(MRM) assays to measure the induction of selected heat shock pro-
teins in RPMI-8226 multiple myeloma cells treated with 0.1 μM 17-
DMAG. Peptides representing each protein were quantiﬁed to high
degrees of precision and accuracy, and the results were compared to
ELISA-based assays directed against the same target. Their assays
demonstrated the drug-induced up-regulation of several isoforms of
Hsp90 and Hsp70. This study is notable in several regards, and is dis-
cussed in more detail in our concluding remarks.
5. Compilation and annotation of Hsp90-interacting proteins
In order to assess proteomics contributions to our understanding of
the Hsp90 interactome, we have complied data from the studies cited
above. These compilations appear in the supplementary materials. The
compiled tables are designed to be working tools for the reader, and in-
clude cross-references to gene aliases and hyperlinks to various database
resources. Supplementary Table 1A lists gene products that bind to
Hsp90 or Hsp90 heterocomplexes. Included in this list are human gene
homologues of Hsp90-binding proteins that were identiﬁed in yeast.
Supplementary Table 1B lists gene products identiﬁed to interact func-
tionally with Hsp90. Included in this list are human gene homologues of
yeast genes that induce SGA or chemical-genetic defects. Supplementary
Table 1C lists the genes that demonstrate both physical and functional in-
teractions. Similarly, we provide a compilation of proteins that interact
with select Hsp90 co-chaperone partners (studies listed in Table 1B,
[24,61,65,72,73]) in Supplementary Table 1D. Supplementary Tables 1Eand F summarize canonical pathways that are enriched within the popu-
lation ofHsp90-binding andHsp90-dependent gene products, respective-
ly. Supplementary Table 1G summarizes enriched GO biological process
ontologies and pathways for human Hsp90 interactors.
Supplementary Tables 2A and B contain lists of the gene products
found to interact with TAP-tagged Hsc82 and Hsp82, respectively, and
is largely identical to the lists originally published by Gong et al. [15].
However, we have added functional annotations for this yeast Hsp90-
binding proteome, linking each gene product to the Sacchaomyces Ge-
nome Database (http://www.yeastgenome.org/). Furthermore, enriched
GOOntologies for Hsc82 andHsp82 Interactors (pb0.5) are given in Sup-
plementary Tables 2C and D, respectively. Enriched MIPS complexes
interacting with Hsc/Hsp82 that were identiﬁed by Gong et al. [15] are
given in Supplemental Table 2E. A table summarizing the general physi-
cal properties, and the top ten protein Pfamdomains andGO slimbiolog-
ical processes of Hsc/Hsp82 interactors derived by Gong et al. [15] are
given in Supplemental Table 2F. Proteins that interacted with both
Hsc82 and Hsp82 are collated in Supplemental Table 2G.
6. Discussion
6.1. Results may vary
Perhaps themost striking feature apparent in the human studies de-
scribed above is the failure to re-discover numerous well-documented
Hsp90 clients. This limitation is consistent with our appreciation that
proteomics techniques usually assay only the most abundant proteins,
that co-chaperone partners dominate the Hsp90 interactome, and that
Hsp90 clients are expressed at low levels. Consistent with the apparent
limitation in the human data, yeast genetic screens have yielded more
than 1000 Hsp90-binding proteins and more than 200 high-quality
functional interactions.
The shallow depth of our current attempts in human cells could be
predicted to amplify minor differences in assay performance, generat-
ing the appearance of disagreement between studies. Consistent with
this interpretation, the greater coverage of the yeast Hsp90 interac-
tome yields much more overlap among yeast studies than has been
obtained among human studies. Thus, the shallow coverage typical
of human studies is one explanation for lack of congruence between
these studies.
Another potential source of in variability between studies is that
isoforms of Hsp90 are not functionally equivalent. The proteomics as-
says of Gong et al. [15] show that discrete yeast Hsp90 isoforms have
distinct interactomes. The chemical genetic assays of McClellan et al.
[18] demonstrate that deletion of heat-inducible isoform of yeast
Hsp90 compromises growth in media containing Hsp90 inhibitor,
while deletion of the yeast Hsp90 cognate does not. These distinc-
tions are also consistent with ﬁndings that the human Hsp90 co-
chaperone GCUNC45A can differentiate Hsp90alpha from Hsp90beta
[74], that recombinant mice deleted in speciﬁc Hsp90 isoforms man-
ifest isoform-speciﬁc developmental defects [75], and with other evi-
dence hinting at isoform-speciﬁc functions [76–79]. Thus, isolation of
mammalian complexes containing Hsp90alpha versus Hsp90beta are
unlikely to give equivalent results, even when the complexes are iso-
lated from the same cell line, yet studies in mammalian systems have
not been designed to address the Hsp90 isoforms.
An additional source of variability is indicated by the ﬁndings of
Gano and Simon [64], showing that the nucleotide-bound state of
Hsp90 profoundly affects its interactions with co-chaperone partners
and client proteins. However, the issue of Hsp90's alternative confor-
mations has typically been ignored when assessing and discussing the
Hsp90 interactome. Because the cellular ATP charge is almost imme-
diately lost upon cell lysis, the Gano and Simon study predicts that
most cell lysis protocols would be incapable of yielding the full com-
plement of Hsp90 chaperone machinery, i.e., past studies may be bi-
ased toward identifying proteins that preferentially interact with
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of the Hsp90 interactome should acknowledge and accommodate
Hsp90's complex conformational lifestyle.
To what extent do the incongruities apparent between studies re-
ﬂect the different cell types assayed? While there have been numer-
ous studies documenting changes in the expression of Hsp90 during
development, there are few studies examining changes in co-chaper-
one expression. Certainly, we can reasonably predict that different
tissues will show different panels of Hps90 clients, but are Hsp90's
co-chaperone coteries regulated by development? Precedents hint
that the answer is “yes.” An analysis of the genomes of 19 disparate
eukaryotic organisms indicates that they differ in the arrays of co-
chaperones that they express [20]. Squirrel monkeys are glucocorti-
coid resistant because they express high levels of FKBP51, which re-
duces glucocorticoid receptor binding afﬁnity [80,81]. Changes in
FKBP52 expression have been observed during differentiation of
male germ cells [82]. Hsp90, Hsp70, STIP1/HOP and p23 levels change
in reticulocytes during their maturation to erythrocytes [83]. Cancer
cells are often observed to over-express chaperones, including
Hsp90 and its subunits. McDowell and co-workers [84] examined
the expression of Hsp90 chaperone proteins in 17 different tumor
types versus normal tissue, ﬁnding that levels of expression of
Hsp90a and b, Aha1, p23 and Tpr2 varied markedly between normal
and tumor tissue. These points do not mean that proteomics assays
have failed to deliver a congruent picture. Rather they argue that
Hsp90 function encompasses degrees of complexity that we have
only begun to appreciate.
Subtleties in experimental design and execution are another po-
tential source of variability. Cellular responses to Hsp90 inhibition
can readily be predicted to depend on the status of the cell popula-
tion. Thus, sub-culturing routines, identity and doses of Hsp90 inhib-
itors applied, and duration of drug exposure all have the potential to
impact the Hsp90-dependent proteome. More dramatically, re-
sponses to Hsp90 inhibitor in vitro may vary considerably from re-
sponses in vivo [71], perhaps reﬂecting the surrounding matrix [85].
Some differences almost certainly reﬂect the different proteomics
techniques used. In future initiatives, the potential impacts of techni-
cal differences can best be addressed by careful descriptions of all as-
pects of the experiment. This recommendation lies at the heart of
modern proteomics guidelines.
6.2. Insights into Hsp90 function
Our compilation of Hsp90's interactions with the cellular prote-
ome suggests that Hsp90 should no longer be viewed as just the “sig-
nal transduction” chaperone. Rather, Hsp90 appears to contribute to
diverse cellular processes and pathways. This is consistent with
Hsp90's emerging role in the function of complex protein machines
such as those involved in RNA processing, RNP assembly, and chro-
matin remodeling (see additional articles in this issue). However, it
is worth noting that proteomics assays ﬁrst revealed Hsp90's involve-
ment therein. Stories that have emerged from yeast studies are also
apparent in the human Hsp90 interactome (Table 3). While disrup-
tions in signal transduction pathways remain a potential explanation
for the wider impacts discussed below, we begin to suspect more di-
rect roles for Hsp90 in these processes.
6.2.1. Hsp90 and glucose metabolism
An analysis of canonical cellular pathways that contain protein
components that interact directly or functionally with Hsp90 reveals
highly signiﬁcant enrichment in enzymes involved in glycolysis and
gluconeogenesis. Cancer cells are well known to have increased aero-
bic glycolysis, a phenomenon known as the Warburg effect [86,87].
Cancer cells also commonly over-express Hsp90, suggesting that
such over-expression might contribute to the Warburg effect. This
contribution could be either through direct interactions betweenHsp90 and glycolytic enzymes, or via indirect impacts on glucose me-
tabolism due to altered signal transduction. In this vein, the well char-
acterized Hsp90-dependent proteins Akt, HIF1α, receptor tyrosine
kinases (e.g., erbB2) and Src have been linked to the Warburg effect
through their ability to enhance the expression and/or activity of glu-
cose transporters and glycolytic enzymes [86,87]. A recent report in-
dicates that treatment of ARPE-19 cells with 17-AAG leads to a
decrease in the levels of key glycolytic enzymes [36]. This effect can
be hypothesized to be a result of the loss of Akt and HIF1α, leading
to the transcriptional suppression of the genes encoding these en-
zymes. Alternatively, Hsp90 may interact more directly with the gly-
colytic enzymes compiled in the supplementary materials. Regardless
of the ﬁner mechanisms, evidence that Hsp90 interacts with the cel-
lular machinery involved in glycolysis and gluconeogenesis suggests
that some of the tumoricidal activity of Hsp90 may be due to diminu-
tion of glycolysis.
6.2.2. Hsp90, the cytoskeleton and intracellular transport
Proteomics assays and genetic HTP analyses indicate that Hsp90
interacts with intracellular trafﬁcking machineries. In yeast, the
Hsp90 interactome is signiﬁcantly enriched in genes/gene products
involved in intracellular vesicle trafﬁcking and Golgi transport
[16,18]. As previously noted [18], these Hsp90-interacting gene prod-
ucts represent virtually all exocytic and endocytic secretory pathways
in yeast, including ER quality control, ubiquitin-regulated protein
trafﬁcking components, and in ESCRT multivesicular sorting pathway.
In support of these conclusions drawn from proteomic data, Okiyo-
neda et al. [88] have recently characterized the components of the
Hsp90 chaperone machine that compose part of the peripheral qual-
ity control system involved in the degradation of damaged plasma
membrane proteins. Furthermore, a role for Hsp90-regulated quality
control and translocation of transmembrane ion channels (CTFR and
hERG, [89–91]) and receptors (MC4R, [92]) at the ER is now estab-
lished. Similarly, the protein:protein interaction networks of steroid
hormone receptors and Hsp90 chaperone machineries intersect at
genes encoding intracellular trafﬁcking proteins [93]. Hsp90's role in
intracellular trafﬁcking is also apparent in the Sba1/p23 protein inter-
action network proposed by Brian Freeman [94]. Here, our compila-
tion of human and yeast Hsp90-interacting proteins implicates 62
human trafﬁcking proteins and 43 human cytoskeleton proteins as
part of the human Hsp90 interactome. Thus, it is highly likely that
roles for yeast Hsp90 in trafﬁcking and cytoskeleton functions are
conserved in human cells.
Because mechanisms behind Hsp90's role in these processes are
largely unknown, we have grouped them into a single concept of traf-
ﬁcking/cytoskeleton. This conceptual grouping acknowledges the po-
tential for overlaps between these cellular networks. The overlap
between these networks is supported by past and current work from
the laboratories of William Pratt and Mario Galigniana that has estab-
lished a role for cytoskeletal components in the Hsp90-dependent
nucleo-cytoplasmic trafﬁcking of steroid hormone receptors (reviewed
in [95] and [96]). A number of mechanisms could account for how
Hsp90, constituents of the cytoskeleton and vesicular trafﬁcking pro-
teins could be found to functionally interact. For instance, inhibition of
Hsp90 could directly inhibit cytoskeleton function, subsequently con-
tributing to synthetic lethality when combined with a deletion in a ves-
icle trafﬁcking gene product. In this regard, Hsp90's interactionwith the
mammalianNudC protein is noteworthy [25,64], becauseNudC iswide-
ly suspected to chaperone the assembly of dynein motor complexes
[97–102]. Hsp90's role in chaperoning myosin motors is similarly note-
worthy [103–105]. It is also important to appreciate that the endoplas-
mic reticulum-speciﬁc Hsp90 isoform GRP94/endoplasmin binds to
most, if not all, Hsp90 inhibitors [106–108]. However, yeast do not ex-
press recognizable homologs of NudC or GRP94, suggesting alternative
mechanisms in yeast, e.g., Hsp90 chaperoning ofmolecularmotors or in-
direct dysregulation due to titration of Hsp90's role in signal
Table 3
Enriched GO terms and pathways for human Hsp90 interacting proteins presented in Supplementary Table 1.
Enriched biological process GO terms for human direct and functional interactorsa.
GO term BP Number of genes GO term BP Number of genes
Protein folding 33 RNA splicing 18
Mitotic cell cycle 42 Post-translational protein modiﬁcation 50
Regulation of ubiquitin-protein
ligase activity
19 Mitochondrial outer
membrane translocase complex assembly
3
Response to unfolded
protein
16 Cellular localization 40
Cell cycle 52 Epidermal growth factor receptor signaling pathway 5
Glycolysis 12 Response to stress 64
Organelle organization 72 Regulation of protein complex disassembly 6
Translation 26 Nuclear export 6
Regulation of molecular
function
52 Somatic cell DNA recombination 4
Regulation of programmed
cell death
44 Cell proliferation 20
Cellular macromolecular
complex assembly
23 Telomere maintenance 4
Cytoskeleton organization 28 Cytoskeleton-dependent intracellular transport 5
Intracellular transport 36 Protein targeting to mitochondrion 4
Organelle ﬁssion 17 Post-Golgi vesicle-mediated transport 5
Microtubule-based process 18 DNA replication 10
RNA transport 10 Regulation of MAP kinase activity 9
Enriched pathways
KEGG_PATHWAY sublist term Number of genes Sublist term Number of genes
Proteasome 15 Prion diseases 6
Glycolysis/gluconeogenesis 13 Pancreatic cancer 8
Antigen processing and
presentation
13 Adherens junction 8
Pyruvate metabolism 9 Propanoate metabolism 5
Gap junction 13 NOD-like receptor signaling pathway 7
Ribosome 12 Glioma 7
Pentose phosphate
pathway
6 Tight junction 11
DNA replication 7 Insulin signaling pathway 11
Spliceosome 13 Epithelial cell signaling in Helicobacter pylori infection 7
MAPK signaling
pathway
21 Regulation of actin cytoskeleton 15
Mismatch repair 5 Cell cycle 10
Panther pathway sublist term Number of genes Sublist term Number of genes
P00049: Parkinson
disease
15 P00024: glycolysis 5
P00060: ubiquitin
proteasome pathway
12 P00029: Huntington disease 12
P02776: serine glycine
biosynthesis
3 P00016: cytoskeletal regulation by Rho GTPase 9
P00006: apoptosis
signaling pathway
12 P00025: hedgehog signaling pathway 5
Reactome pathway sublist term Number of genes Sublist term Number of genes
REACT_11045: signaling by Wnt 20 REACT_578: apoptosis 21
REACT_13635: regulation of
activated PAK-2p34 by
proteasome
16 REACT_6185: HIV infection 24
REACT_383: DNA replication 22 REACT_13: metabolism of amino acids 22
REACT_6850: Cdc20: Phospho-APC/C
mediated degradation
of Cyclin A
18 REACT_1762: 3′-UTR-mediated translational regulation 17
REACT_152: cell cycle, mitotic 41 REACT_6167: inﬂuenza infection 20
REACT_9035: APC/C: Cdh1-mediated
degradation of Skp2
17 REACT_71: gene expression 34
REACT_1538: cell cycle
checkpoints
22 REACT_12508: metabolism of nitric oxide 4
REACT_17015: metabolism
of proteins
30 REACT_1505: integration of energy metabolism 20
REACT_474: metabolism of
carbohydrates
18 REACT_15380: diabetes pathways 22
Human genes were compiled from Supplementary Tables 1A and B, and analyzed for enrichment in GO biological processes, and KEGG, Panther and Reactome Pathways utilizing
DAVID Bioinformatics Resources 6.7 (NIAID).
a Selected GO terms are listed to remove redundancy and highlight major enriched biological processes (from Supplemental Table 1G).
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ﬁcking processes are largely unknown, proteomics assays to date provide
strong evidence for an Hsp90 connection.
6.3. Future prospects
Proteomics is often described as a hypothesis-generating discipline,
and studies to date have delivered several new hypothetical functions
for Hsp90 and newmodels for its regulation. Many of these hypotheses
will require a deeper qualitative and quantitative understanding of the
human Hsp90 interactome, and the interactomes of its co-chaperone
partners. Most pressing, perhaps, is the need for proteomics assays ca-
pable of mining Hsp90's clientele.
This depth may be obtainable using orthogonal fractions of the
Hsp90 interactome (e.g., MuDPIT or GeLC–MS), or using techniques
such as ion mobility mass spectrometry to further fractionate the ion
stream. Because such fractionations can induce technical variability,
they will likely require isotope-coding strategies that allow samples to
be mixed prior to chromatographic separation. MS instrumentation
and proteomics software themselves continue to advance at a breath-
taking pace (e.g., [109]), and will certainly enhance our penetration
into the Hsp90 interactome. Despite the exact technologies utilized,
however, the next generation of Hsp90 proteomics studies will require
enhanced quantitative rigor, featuring the binding controls, biological
replicates, and statistical validations necessary to ﬁrmly differentiate
meaningful cellular responses from technical noise.
One of the main challenges now raised is that of differentiating di-
rect relationships from indirect relationships. In many HTP datasets, it
is not possible to differentiate direct relationships (e.g., co-chaperones
and Hsp90:client relationships) from indirect relationships (e.g., tran-
scriptional impacts and Hsp90-dependent nodes within larger path-
ways). To date, this differentiation has required traditional, tightly
focused characterizations of individual Hsp90-associated gene prod-
ucts. An HTP method for making this distinction is greatly needed.
Proteomics assays of Hsp90 function also hold promise in addres-
sing pharmacodynamic discrepancies observed between tumors in
vivo vs. tumor cell cultures [71,85], and the poor predictive potential
of peripheral blood mononuclear cells currently serving as pharmaco-
dynamic proxies in vivo [110]. This promise is apparent in the work of
Remily-Wood et al. [51], demonstrating that it should be wholly fea-
sible to monitor tumor biopsy specimens for speciﬁc in vivo responses
to Hsp90 inhibition. Targeted high-sensitivity MS-based assays hold
similar promise for other questions that require efﬁcient assessment
of limited numbers of cells, e.g., microdissections of tumors, tumor
stem cells, and tumor specimen banks. Achieving this promise will re-
quire initial surveys to discover high-conﬁdence, readily detectable
peptides representing proteins that respond to Hsp90 inhibition, fol-
lowed by rigorous validation of these peptides as quantitative phar-
mocodynamic reporters.
Researchers utilizing a variety of proteomics techniques have pro-
vided an illuminating picture how Hsp90 and its regulatory subunits
support protein folding in vivo. None-the-less, a great deal of oppor-
tunity remains. Additional proteomics assays of Hsp90's functions
and partners have the potential to answer mysteries old and new,
but will require careful appreciation of the pivotal parameters identi-
ﬁed in studies performed to date.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamcr.2011.08.013.
7. Abbreviations
17-AAG 17-allylamino-17-demethoxygeldanamycin
17-DMAG 17-desmethoxy-
17-N,N-dimethylaminoethylaminogeldanamycin
2-D PAGE two-dimensional polyacrylamide gel electrophoresis
using sodium dodecyl sulfate in the second dimensionDIGE difference gel electrophoresis
ELISA enzyme-linked immunosorbent assay
HTP high throughput
ICAT isotope-coded afﬁnity tag
iTRAQ isobaric tags for relative and absolute quantitation
LC–MS/MS liquid chromatography eluting directly into an electro-
spray tandem mass spectrometer
MALDI-TOF matrix-assisted laser desorbtion/ionization time-of-ﬂight
mass spectrometry
MTOC microtubule organizing center
MRM multiple reaction monitoring
MS mass spectrometry or mass spectrometer
MS/MS tandem mass spectrometry or tandem mass spectrometer
RNP ribonucleoprotein
SGA synthetic genetic array
SIM selected ion monitoring
SRM selected reaction monitoring
TAP tandem afﬁnity puriﬁcationAcknowledgements
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